Back to All Events


  • The Great Hall at Cooper Union 7 East 7th Street New York, NY, 10003 United States (map)

9:00 AM

Doors open

9:30 AM

Opening remarks

9:45 AM

LSD Microdosing Study: Psychedelics and Behavioral Effects: What’s in a Dose?

Kim Kuypers, Ph.D.
Researcher and Assistant Professor, Maastricht University, The Netherlands

10:30 AM

Neuroscience Findings from Psilocybin Neuroimaging Studies

Taylor Lyons, Ph.D. (candidate)
Postgraduate Researcher, Psychedelic Research Group, Imperial College, London

11:15 AM


11:30 AM

Clinical Trials on Psilocybin as a Treatment for Major Depressive Disorder

Malynn Utzinger, M.D.
Director of Integrative Medicine, Co-Founder, Usona Institute
Director of Integrative Practices, Promega Corporation

12:15 PM

Psilocybin for Depression: Introducing the ACE Model (Accept, Connect, Embody)

Rosalind Watts, Ph.D.
Clinical Psychologist, Psychedelic Research Group, Imperial College, London

Ashleigh Murphy-Beiner
Assistant Psychologist, Imperial Psychedelic Research Group

1:00 PM


2:10 PM

The Potential for Healing and Harm with 5-MeO-DMT

Alan Davis, Ph.D.
Licensed Clinical Psychologist, Assistant Professor at The Ohio State University; Adjunct Assistant Professor at Johns Hopkins University

2:55 PM

Ketamine and Psychiatry

Elias Dakwar, M.D.
Associate Professor of Psychiatry, Columbia University

3:40 PM


4:10 PM

Update on MAPS’ MDMA for PTSD clinical trials

Charlotte Harrison
Clinical Trial Leader, MAPS Public Benefit Corporation

4:55 PM

Dispelling the Lies that the Psychedelic Community Believes About Drugs

Carl Hart, Ph.D
Ziff Professor of Psychology (in Psychiatry), Departments of Psychology and Psychiatry, Columbia University

5:45 PM


Earlier Event: October 11
Later Event: October 13